Skip to content
  • Tuesday, 27 October 2026
  • 11:19 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Sanofi and Regeneron Expand Landmark Pharma Alliance in $8bn Deal to Co-Develop Next-Generation Long-Acting Antibodies
Pharmaceutical R&D

Sanofi and Regeneron Expand Landmark Pharma Alliance in $8bn Deal to Co-Develop Next-Generation Long-Acting Antibodies

Teuku Ryan Oct 1, 2026 0

Building upon one of the most successful and enduring scientific partnerships in the history of the modern pharmaceutical industry, French…

Read More
Pharmaceutical R&D

Regeneron and CytomX extend cancer therapy partnership to $4bn deal

Teuku Ryan Jun 5, 2026 0

Regeneron Pharmaceuticals and CytomX Therapeutics have significantly expanded their strategic research and licensing collaboration, aiming to pioneer the development of…

Read More
Pharmaceutical R&D

Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies

Teuku Ryan May 20, 2026 0

Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…

Read More
Pharmaceutical R&D

Regeneron cuts White House pricing deal, offers new gene therapy for free – Pharmaceutical Technology

Teuku Ryan Apr 26, 2026 0

Regeneron Pharmaceuticals has entered into a significant drug pricing agreement with the White House, marking a pivotal moment in the…

Read More
Pharmaceutical R&D

Regeneron Pharmaceuticals and Telix Pharmaceuticals Forge Strategic Alliance to Advance Precision Oncology Through Radiopharmaceutical Innovation

Teuku Ryan Apr 14, 2026 0

Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a significant partnership aimed at accelerating the development and commercialization of novel radiopharmaceutical…

Read More
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu VaccineLudwig Cancer Research Study Reveals Novel Combination Therapy for Acute Myelogenous Leukemia Targeting Epigenetic Barriers to Cell DifferentiationFrom RAG to Agentic AI: Building the Next Generation of Intelligent Enterprise SystemsNavigating the 2026 Frontier AI Landscape: Why ChatGPT Work and GPT-5.6 Changed the Enterprise Software Equation
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ